Safety concerns delay Epogin's Japanese approval for chemotherapy-induced anaemia
This article was originally published in Scrip
Executive Summary
Roche's Japanese subsidiary Chugai has been advised that its submission for the recombinant erythropoietin product Epogin (epoetin beta) for the additional indication of chemotherapy-induced anaemia (CIA) is unlikely to be approved in its current form.